SARcode's Dry Eye Drug Hits Endpoint in First Phase III Trial

SARcode Bioscience Inc. cleared the first hurdle in its Phase III program testing dry eye candidate lifitegrast, with the drug nailing its primary endpoint in the first pivotal trial, demonstrating biologic activity against ocular surface damage.